THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. (Q37860314)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Xavier Montalban

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Carlos Vila

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Stephen Clissold

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

627-637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

Rehabilitation in practice: Spasticity management

21 January 2018

1 reference

Prevalence and treatment of spasticity reported by multiple sclerosis patients

21 January 2018

1 reference

Cannabis use in patients with multiple sclerosis

21 January 2018

1 reference

Combined cannabinoid therapy via an oromucosal spray

21 January 2018

1 reference

The medicinal use of cannabis in the UK: results of a nationwide survey.

21 January 2018

1 reference

Cannabinoid pharmacology: the first 66 years

21 January 2018

1 reference

Endocannabinoids and the regulation of their levels in health and disease

21 January 2018

1 reference

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

Cannabis use and risk of lung cancer: a case-control study

21 January 2018

1 reference

Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?

21 January 2018

1 reference

Stop using the Ashworth Scale for the assessment of spasticity.

21 January 2018

1 reference

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

21 January 2018

1 reference

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

21 January 2018

1 reference

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

21 January 2018

1 reference

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

21 January 2018

1 reference

A community survey of adverse effects of cannabis use.

21 January 2018

1 reference

Comorbid cannabis use and panic disorder: short term and long term follow-up study

21 January 2018

1 reference

Long-term effects of exposure to cannabis

21 January 2018

1 reference

Managing the symptoms of multiple sclerosis: a multimodal approach

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.11.47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21456949%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference